Ardelyx Inc (ARDX) : Cormorant Asset Management scooped up 572,738 additional shares in Ardelyx Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 2,071,964 shares of Ardelyx Inc which is valued at $32,115,442.Ardelyx Inc makes up approximately 3.61% of Cormorant Asset Management’s portfolio.
Other Hedge Funds, Including , Jacobs Levy Equity Management Inc sold out all of its stake in ARDX during the most recent quarter. The investment firm sold 10,000 shares of ARDX which is valued $155,000.Proshare Advisors boosted its stake in ARDX in the latest quarter, The investment management firm added 4,311 additional shares and now holds a total of 32,886 shares of Ardelyx Inc which is valued at $475,203. Ardelyx Inc makes up approx 0.01% of Proshare Advisors’s portfolio.Rhumbline Advisers boosted its stake in ARDX in the latest quarter, The investment management firm added 5,880 additional shares and now holds a total of 30,619 shares of Ardelyx Inc which is valued at $396,516.Tiaa Cref Investment Management boosted its stake in ARDX in the latest quarter, The investment management firm added 12,871 additional shares and now holds a total of 84,630 shares of Ardelyx Inc which is valued at $1,095,959. First Manhattan Co added ARDX to its portfolio by purchasing 1,053,628 company shares during the most recent quarter which is valued at $14,065,934. Ardelyx Inc makes up approx 0.09% of First Manhattan Co’s portfolio.
Ardelyx Inc closed down -0.05 points or -0.32% at $15.35 with 1,68,359 shares getting traded on Monday. Post opening the session at $15.45, the shares hit an intraday low of $14.7 and an intraday high of $15.55 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Ardelyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery development and commercialization of minimally-systemic small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat cardio-renal GI and metabolic diseases. The Company utilizing its platform discovered and designed its lead product candidate tenapanor which in clinical studies has demonstrated the ability to improve the symptoms of constipation-predominant irritable bowel syndrome (IBS-C) and to reduce the absorption of both dietary sodium and phosphorus. The Company in collaboration with AstraZeneca has completed a Phase IIb clinical trial evaluating tenapanor in patients with IBS-C. It also has other product candidates under development such as RDX002 for the treatment of Hyperphosphatemia RDX009 for the treatment of IBD Short Bowel Syndrome and non-alcoholic steatohepatitis (NASH) and RDX013 for the treatment of hyperkalemia.